About Viridian Bio
Viridian Bio is a company based in Philadelphia (United States) founded in 2019 by Tomas Kiselak and Peter Harwin was acquired by MiRagen in October 2020. Viridian Bio has raised $29 million across 2 funding rounds from investors including MiRagen. Viridian Bio operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Philadelphia, United States
- Founders Tomas Kiselak, Peter Harwin
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Viridian Bio
Viridian Bio has successfully raised a total of $29M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $27 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Viridian Bio
Viridian Bio has secured backing from 1 investor. Prominent investors backing the company include MiRagen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Locked | Locked | Locked |
Investor details for Viridian Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Viridian Bio
Investment portfolio details for Viridian Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Viridian Bio
Detailed financials for Viridian Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Viridian Bio Comparisons
Peer comparison for Viridian Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Viridian Bio
Viridian Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Viridian Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Viridian Bio
Complete news archive for Viridian Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viridian Bio
Viridian Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Viridian Bio is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Viridian Bio is a funded company, having raised a total of $29M across 2 funding rounds to date.
Viridian Bio was established in 2019 in Philadelphia, United States, within the biotechnology sector. A platform is utilized to validate scientific findings and identify differentiated molecules addressing high unmet medical needs. Operations focus on aiding the transition of basic research into viable products, with new companies formed to handle commercialization based on confirmed hypotheses.
Viridian Bio's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Viridian Bio has 1 investor. Key investors include MiRagen.